Results 201 to 210 of about 3,233 (250)
Some of the next articles are maybe not open access.
International Anesthesiology Clinics, 1988
Clearly, many aspects of the action of neuromuscular blockers remain poorly understood at the molecular level. In the case of competitive blockers, blockade of EPPs by competitive binding to the ACh receptor site accounts for the most clinically important aspect of blockade.
C J, Lingle, J H, Steinbach
openaire +2 more sources
Clearly, many aspects of the action of neuromuscular blockers remain poorly understood at the molecular level. In the case of competitive blockers, blockade of EPPs by competitive binding to the ACh receptor site accounts for the most clinically important aspect of blockade.
C J, Lingle, J H, Steinbach
openaire +2 more sources
Veterinary Clinics of North America: Equine Practice, 2002
In summary, with proper vigilance, neuromuscular blocking agents can be used safely in anesthetized equine patients to optimize conditions for certain surgical procedures. By appropriate use of neuromuscular monitoring techniques and reversal agents, residual blockade and muscle weakness should be avoided, allowing the horse to recover to standing ...
openaire +2 more sources
In summary, with proper vigilance, neuromuscular blocking agents can be used safely in anesthetized equine patients to optimize conditions for certain surgical procedures. By appropriate use of neuromuscular monitoring techniques and reversal agents, residual blockade and muscle weakness should be avoided, allowing the horse to recover to standing ...
openaire +2 more sources
LITHIUM CARBONATE AND NEUROMUSCULAR BLOCKING AGENTS
Survey of Anesthesiology, 1977The effects of lithium carbonate on the responses to five neuromuscular blocking agents were evaluated in dogs anesthetized with halothane (1 per cent) and N2O (60 per cent) in O2. Latency (time from first twitch-height depression to maximal blockade), maximal twitch-height depression, and times to return to 50 per cent and 100 per cent control twitch ...
G E, Hill, K C, Wong, M R, Hodges
openaire +2 more sources
Neuromuscular Blocking Agents and Neuromuscular Diseases
2000Acquired neuromuscular diseases or congenital disorders either affect the neuromuscular transmission or the muscle itself. When the neuromuscular transmission is involved, two pathophysiological mechanisms must be distinguished: the abnormality of the nicotinic receptor at the endplate (myasthenia gravis, upregulation of the receptor) and the ...
Benoît Plaud, François Donati
openaire +1 more source
Critical Care Medicine, 1993
On logical grounds, the term “neuromuscular-blocking agent” might be applied to any drug, the primary action of which is to interrupt neuromuscular transmission. This chapter discusses those drugs of which the primary site of action is the postjunctional motor endplate cholinoceptors and drugs that are used as muscle relaxants in anaesthetic practice ...
Pam Dulin, Cheryl Williams
openaire +1 more source
On logical grounds, the term “neuromuscular-blocking agent” might be applied to any drug, the primary action of which is to interrupt neuromuscular transmission. This chapter discusses those drugs of which the primary site of action is the postjunctional motor endplate cholinoceptors and drugs that are used as muscle relaxants in anaesthetic practice ...
Pam Dulin, Cheryl Williams
openaire +1 more source
Disadvantages of Neuromuscular Blocking Agents
Veterinary Clinics of North America: Small Animal Practice, 1992Neuromuscular blocking agents have few indications and significant contraindications or problems associated with their use. The need for controlled ventilation and the difficulties of monitoring anesthetic depth when using neuromuscular blocking agents are overriding factors that mitigate against their routine use.
openaire +2 more sources
The Danger With Neuromuscular Blocking Agents
Journal of Emergency Nursing, 2004Susan Paparella, Ches-mont Chapter, is Director for Consulting Services,Institute for Safe Medication Practices (ISMP*), Huntingdon Valley, Pa, and a member of ENA’s ED Safety Workgroup. For reprints, write: Susan Paparella, RN, MSN, 1800 Byberry Rd, Suite 800, Huntingdon Valley, PA 19006; E-mail: spaparella@ismp.org. J Emerg Nurs 2004;30:250-2.
openaire +2 more sources
Neuromuscular Blocking Agents in ARDS
New England Journal of Medicine, 2010In this issue of the Journal, Papazian and colleagues1 present intriguing results of their study examining neuromuscular blockade in patients with severe, early acute respiratory distress syndrome (ARDS). The investigators randomly assigned 340 patients to receive the neuromuscular blocking agent cisatracurium or placebo for a period of 48 hours.
openaire +2 more sources
Viral agents in neuromuscular pathology
In recent years, viral infections have been increasingly identified as major players in neuromuscular pathologies. This chapter presents an overview of the evidence and future directions for virus-induced neuromuscular disorders. Information is integrated on the global burden of these diseases related to epidemiology, clinical features, diagnosis ...Abhay Kumar, Singh +3 more
openaire +2 more sources
2016
Many drugs used for induction or maintenance of anaesthesia provide a degree of skeletal muscle relaxation, but in general this is only mild to moderate at a surgical plane of anaesthesia. This chapter looks at different ways to achieve more profound muscle relaxation, neuromuscular blocking agents (NMBAs) and their mechanism, monitoring the ...
Renu Agarwal, Priya Mathur
openaire +2 more sources
Many drugs used for induction or maintenance of anaesthesia provide a degree of skeletal muscle relaxation, but in general this is only mild to moderate at a surgical plane of anaesthesia. This chapter looks at different ways to achieve more profound muscle relaxation, neuromuscular blocking agents (NMBAs) and their mechanism, monitoring the ...
Renu Agarwal, Priya Mathur
openaire +2 more sources